Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

Related Citations for PubMed (Select 22264679)

1.

The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.

Wu GH, Auvinen A, Yen AM, Hakama M, Tammela TL, Stenman UH, Kujala P, Ruutu M, Chen HH.

Eur Urol. 2012 May;61(5):1011-8. doi: 10.1016/j.eururo.2012.01.008. Epub 2012 Jan 14.

PMID:
22264679
2.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.

PMID:
21601352
3.

Towards an optimal interval for prostate cancer screening.

van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.

Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10.

PMID:
21840117
4.

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group.

Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.

PMID:
23759326
5.

Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.

Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE.

Eur Urol. 2012 May;61(5):865-74. doi: 10.1016/j.eururo.2011.11.007. Epub 2011 Nov 12.

PMID:
22104593
6.

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A.

Eur Urol. 2009 Oct;56(4):584-91. doi: 10.1016/j.eururo.2009.07.018. Epub 2009 Jul 28.

PMID:
19660851
7.

Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.

Yli-Hemminki TH, Laurila M, Auvinen A, Määttänen L, Huhtala H, Tammela TL, Kujala PM.

BJU Int. 2013 Oct;112(6):735-41. doi: 10.1111/bju.12153. Epub 2013 Jun 7.

PMID:
23746332
8.

A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.

Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.

Eur Urol. 2013 Apr;63(4):627-33. doi: 10.1016/j.eururo.2012.07.029. Epub 2012 Jul 20.

PMID:
22841675
9.

Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ.

Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.

PMID:
22704366
10.

Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.

Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P.

Eur Urol. 2011 Sep;60(3):554-63. doi: 10.1016/j.eururo.2011.05.047. Epub 2011 Jun 1.

PMID:
21664039
11.

Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.

Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J.

Eur Urol. 2013 Nov;64(5):703-9. doi: 10.1016/j.eururo.2013.05.024. Epub 2013 May 17.

PMID:
23721957
12.

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH.

Eur J Cancer. 2010 Jan;46(2):377-83. doi: 10.1016/j.ejca.2009.09.008. Epub 2009 Oct 3.

PMID:
19804966
13.

Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.

14.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
15.

Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, Roobol MJ.

Eur Urol. 2014 Feb;65(2):329-36. doi: 10.1016/j.eururo.2013.08.005. Epub 2013 Aug 11.

PMID:
23954085
16.

Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.

Rove KO, Crawford ED.

World J Urol. 2012 Apr;30(2):137-42. doi: 10.1007/s00345-011-0799-4. Epub 2011 Nov 25. Review.

PMID:
22116599
17.

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J.

Eur Urol. 2013 Jan;63(1):101-7. doi: 10.1016/j.eururo.2012.08.066. Epub 2012 Sep 5.

PMID:
22980443
18.

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28.

PMID:
18262712
19.

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.

PMID:
22104592
20.

Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial.

Auvinen A, Määttänen L, Finne P, Stenman UH, Aro J, Juusela H, Rannikko S, Tammela TL, Hakama M.

Int J Cancer. 2004 Oct 10;111(6):940-3.

PMID:
15300807
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk